Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Deffered Revenue: 2015-2024

Historic Non-Current Deffered Revenue for Adma Biologics (ADMA) over the last 9 years, with Dec 2024 value amounting to $1.5 million.

  • Adma Biologics' Non-Current Deffered Revenue fell 9.03% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 9.03%. This contributed to the annual value of $1.5 million for FY2024, which is 8.46% down from last year.
  • Per Adma Biologics' latest filing, its Non-Current Deffered Revenue stood at $1.5 million for FY2024, which was down 8.46% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Non-Current Deffered Revenue peaked at $2.1 million during FY2020, and registered a low of $1.5 million during FY2024.
  • Its 3-year average for Non-Current Deffered Revenue is $1.7 million, with a median of $1.7 million in 2023.
  • Data for Adma Biologics' Non-Current Deffered Revenue shows a maximum YoY decreased of 8.46% (in 2024) over the last 5 years.
  • Adma Biologics' Non-Current Deffered Revenue (Yearly) stood at $2.1 million in 2020, then declined by 6.74% to $2.0 million in 2021, then dropped by 7.23% to $1.8 million in 2022, then declined by 7.80% to $1.7 million in 2023, then decreased by 8.46% to $1.5 million in 2024.